Welcome to our dedicated page for Biorestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on Biorestorative Therapies stock.
BioRestorative Therapies Inc (BRTX) is a pioneering biotechnology company advancing autologous stem cell therapies for chronic disc/spine conditions and metabolic disorders. This dedicated news hub provides investors and industry professionals with essential updates on clinical developments, regulatory milestones, and corporate announcements.
Access timely information about BRTX-100 clinical trials, metabolic program research, financial disclosures, and strategic partnerships. Our curated collection ensures transparent tracking of progress in regenerative medicine, featuring official press releases and verified news coverage.
Key focus areas include FDA communications, peer-reviewed study results, intellectual property developments, and executive leadership updates. Users benefit from centralized access to critical information for informed decision-making without promotional bias.
Bookmark this page for ongoing updates on BioRestorative Therapies' innovative work in cell-based medical solutions. Check regularly for new developments in non-surgical treatment alternatives and metabolic health innovations.
BioRestorative Therapies (NASDAQ: BRTX) has announced a research collaboration with Dr. Tore Bengtsson from Stockholm University to explore brown fat tissue's biology and its role in heat production. The collaboration aims to enhance understanding of the thermogenic response of BioRestorative's proprietary cell lines. This research is expected to benefit the company's ThermoStem program, which targets obesity and metabolic disorders using brown adipose-derived stem cells to promote caloric burning and improve metabolic health.
BioRestorative Therapies (NASDAQ: BRTX) announced a significant milestone with the U.S. Patent and Trademark Office granting a notice of allowance for a key patent related to its BRTX-100 clinical program.
This patent covers methods for preparing a stem cell population aimed at treating chronic lumbar disc disease, enhancing the therapeutic viability of the cells in low oxygen environments typical of damaged discs. CEO Lance Alstodt emphasized this development as crucial for fortifying the company’s intellectual property and clinical advancement in a promising market.
BioRestorative Therapies has announced the initiation of site selection for its Phase 2 clinical trial targeting chronic lumbar disc disease with BRTX-100. This double-blind, randomized trial will evaluate the safety and preliminary efficacy of an intradiscal injection in up to 99 patients across 15 centers in the U.S. The company emphasizes selecting sites with proven experience in similar studies to ensure adherence to good clinical practice standards.
BioRestorative Therapies announced its uplisting to Nasdaq and will celebrate by ringing the closing bell on February 7, 2022. CEO Lance Alstodt emphasized the company's commitment to validating its technology through regulatory processes, aiming to lead in the cellular therapy market. Over the past decade, BioRestorative has established a strong foundation in science and clinical translation while planning to expand its therapeutic pipeline. The company's core programs focus on BRTX-100 for disc/spine disease and ThermoStem for metabolic disorders.
BioRestorative Therapies, Inc. (NASDAQ: BRTX) announced a notice of allowance from the Japanese Patent Office for a patent linked to its ThermoStem® Program. This notice, issued on January 26, 2022, covers implantable three-dimensional scaffolds and brown adipocytes derived from human stem cells, aimed at delivering metabolically active cells for treating metabolic disorders. CEO Lance Alstodt emphasized this strengthens their global patent portfolio and highlights ThermoStem® as a viable treatment for diabetes and obesity, addressing significant unmet medical needs.
BioRestorative Therapies (NASDAQ:BRTX) has appointed Robert Paccasassi as Vice President of Quality Assurance/Regulatory Compliance. With over 25 years of experience in biotech and quality systems, he will oversee quality initiatives as the company begins patient enrollment for a Phase 2 clinical trial targeting chronic lumbar disc disease. Paccasassi’s past roles include significant positions at Merck KGaA, Regeneron, Millennium, and Biogen Idec. This leadership appointment aims to enhance the company's compliance and quality control in its stem cell therapy programs.
BioRestorative Therapies (BRTX) will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, scheduled virtually from January 10-13, 2022. CEO Lance Alstodt will lead a pre-recorded presentation available starting January 10 at 7 a.m. ET. Attendees can access the link for the presentation here. The presentation will also be archived for 30 days on the company’s website. BRTX focuses on stem cell-based treatments, including the brtxDISC™ program for spine disease and the ThermoStem® program targeting metabolic disorders.
BioRestorative Therapies announced a Phase I STTR grant of $256,000 from the NIH to evaluate the therapeutic effects of its hypoxic cultured bone marrow-derived stem cells (BRTX-100) with a novel PEG-peptide hydrogel. This collaboration with Dr. Lori Setton aims to optimize therapeutic delivery methods. Successful completion of this phase could lead to applications for Phase II funding, potentially reaching $1 million. The grant demonstrates recognition of BioRestorative's innovative approach to stem cell therapies, particularly in treating chronic lower back pain.
BioRestorative Therapies, Inc. (NASDAQ:BRTX) has signed a Master Service Agreement with PRC Clinical to manage its Phase 2 clinical trial for BRTX-100, aimed at treating chronic lumbar disc disease. PRC Clinical brings extensive experience and innovative technology to the collaboration. CEO Lance Alstodt emphasized this partnership as a significant step towards clinical development. The trial's success could advance BioRestorative's mission to develop cell-based therapeutics, as they aim for primary endpoint readouts in the near future.
